Higher-Than-Recommended Lenalidomide Dosing Is Safe in Transplant-Eligible Newly Diagnosed Multiple Myeloma with Renal Impairment
High renal response without renal decline supports the safety and efficacy of lenalidomide doses higher than recommended during induction in transplant-eligible newly diagnosed multiple myeloma patients.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
